Novo Nordisk A/S
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Company News
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk A/S $NVO Stock Sold by Eastern Bank
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
Novo provides update on the denecimig Biologics License Application (BLA) in the US
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies